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literature on blood-based biomarkers and their potential 
value for improving the management of patients with a 
diffuse glioma. Incorporation of the study of circulating 
molecular biomarkers in clinical trials is essential for fur-
ther assessment of the potential of liquid biopsies in this 
context.
Keywords Malignant glioma · Minimally invasive 
biomarkers · Liquid biopsies · Molecular diagnostics
Introduction
Diffuse gliomas are the most frequent primary malignant 
tumors of the central nervous system [182]. Each year in 
the United States, approximately 17,000 patients are diag-
nosed with a diffuse glioma [119]. Nowadays, magnetic 
resonance (MR) imaging is the principal imaging modal-
ity for patients with suspected brain lesions [123]. For a 
definitive diagnosis of tumor type and malignancy grade, 
tumor tissue (obtained via biopsy or resection) is required 
[99]. Both low- and high-grade malignant diffuse gliomas 
Abstract Diffuse gliomas are the most common malig-
nant primary tumors of the central nervous system. Like 
other neoplasms, these gliomas release molecular infor-
mation into the circulation. Tumor-derived biomarkers 
include proteins, nucleic acids, and tumor-derived extra-
cellular vesicles that accumulate in plasma, serum, blood 
platelets, urine and/or cerebrospinal fluid. Recently, also 
circulating tumor cells have been identified in the blood 
of glioma patients. Circulating molecules, vesicles, plate-
lets, and cells may be useful as easily accessible diag-
nostic, prognostic and/or predictive biomarkers to guide 
patient management. Thereby, this approach may help 
to circumvent problems related to tumor heterogeneity 
and sampling error at the time of diagnosis. Also, liquid 
biopsies may allow for serial monitoring of treatment 
responses and of changes in the molecular characteristics 
of gliomas over time. In this review, we summarize the 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00401-015-1399-y) contains supplementary 
material, which is available to authorized users.
M. G. Best · N. Sol · S. Zijl · J. C. Reijneveld · P. Wesseling · 
T. Wurdinger (*) 
Neuro-oncology Research Group, VU University Medical Center, 
Cancer Center Amsterdam, CCA Room 3.20, Boelelaan 1117, 
1081 HV Amsterdam, The Netherlands
e-mail: t.wurdinger@vumc.nl
M. G. Best · T. Wurdinger 
Department of Neurosurgery, VU University Medical Center, 
Cancer Center Amsterdam, Amsterdam, The Netherlands
M. G. Best · P. Wesseling 
Department of Pathology, VU University Medical Center, Cancer 
Center Amsterdam, Amsterdam, The Netherlands
N. Sol · J. C. Reijneveld 
Department of Neurology, VU University Medical Center, Cancer 
Center Amsterdam, Amsterdam, The Netherlands
P. Wesseling 
Department of Pathology, Radboud University Medical Center, 
Nijmegen, The Netherlands
T. Wurdinger 
Department of Neurology, Massachusetts General Hospital, 
Harvard Medical School, Boston, MA, USA
T. Wurdinger 
thromboDx BV, Amsterdam, The Netherlands
850 Acta Neuropathol (2015) 129:849–865
1 3
are characterized by extensive, infiltrative growth in the 
brain parenchyma, rendering complete resection of the 
tumor impossible [36]. Even with the current standard 
treatment consisting of (combinations of) surgery, temo-
zolomide (TMZ)—or procarbazine–lomustine–vincristine 
(PCV)-based chemotherapy—and radiotherapy [159, 160], 
glioma patients still face a poor prognosis. In general, 
the median survival of low-grade glioma (LGG; WHO 
grade II) patients is 5–10 years, 3 to more than 10 years 
for WHO grade III oligodendrogliomas, 2 years for WHO 
grade III astrocytomas, and 12–18 months for WHO grade 
IV gliomas/glioblastomas [133]. Bailey and Cushing pro-
posed the first systematic and detailed classification of 
gliomas in 1926 [7]. In the course of the following dec-
ades, the morphological diagnosis (typing and grading) of 
these tumors was further refined, culminating in the most 
recent, i.e., 2007 World Health Organization (WHO) clas-
sification of diffuse gliomas [101]. Meanwhile, it is now 
fully clear that for optimal management of patients with a 
diffuse glioma more precise classification of these tumors 
is needed, and that molecular markers hold great promise 
in this respect [100, 108, 118, 170, 179, 180]. For instance, 
it has become clear that patients with grade III 1p/19q co-
deleted anaplastic oligodendrogliomas generally have a 
better prognosis than patients with other grade III glioma 
subtypes and that IDH1 mutant (secondary) glioblastomas 
tend to have a better outcome than IDH1 wild-type grade 
III astrocytomas [164].
Biomarkers are defined here as objectively measurable 
parameters that have additional (diagnostic, prognostic, 
predictive and/or monitoring) value to clinical parameters 
such as tumor type and grade, age, and performance status 
[81, 109, 133]. Detection of molecular glioma biomarkers 
such as MGMT promoter methylation, IDH1/IDH2 muta-
tion, 1p/19q co-deletion, epidermal growth factor receptor 
(EGFR) amplification and EGFR variant III (EGFRvIII) 
expression in tumor tissue is increasingly being used in 
clinical care [64, 70, 183]. For example, 1p/19q co-deletion 
in diffuse gliomas serves as a diagnostic, prognostic, and 
predictive biomarker (indicating resp. the diagnosis of oli-
godendroglioma, improved survival and improved response 
to first-line PCV chemotherapy and radiation) [166]. New 
insights into gliomagenesis [22, 121, 169] such as the poten-
tial role of glioma stem-like cells [154], intratumoral hetero-
geneity [122, 156] and molecular subtypes [125, 161, 174] 
have revealed novel potential therapeutic targets. Exam-
ples are vascular endothelial growth factor (VEGF) which 
can be targeted by the monoclonal antibody bevacizumab, 
IDH1/IDH2 mutations and the development of the specific 
inhibitor AGI-5198, and EGFRvIII with the peptide vaccine 
rindopepimut [6, 35, 57, 135]. Also, mutated IDH1 has been 
reported as a marker indicating that more radical surgical 
glioma resection may be of benefit for the patient [14].
Non-small cell lung cancer and melanoma are at the 
forefront of molecular diagnostics, with a variety of treat-
ments targeting molecular alterations defining specific can-
cer subtypes (e.g., BRAF, EGFR, ALK alterations). Accurate 
molecular diagnostics is essential for personalized therapies 
to assess patient candidacy for a particular therapy based 
on drug-sensitizing genetic alterations of the tumor. These 
specific genetic pathway alterations that are the target of a 
drug are regarded as molecular companion diagnostic bio-
markers. The FDA has issued guidelines stating that they 
will only review such targeted drugs for approval in the 
context of corresponding in vitro companion diagnostics 
[146]. Companion diagnostics for targeted cancer treat-
ments simplifies the drug discovery process, makes clini-
cal trials more efficient and informative, and can be used 
to individualize the therapy of cancer patients. There is an 
urgent need to develop molecular diagnostics to better iden-
tify the patients that respond to expensive targeted thera-
pies. Currently, mutational profiles of cancer patients are 
determined in tumor tissues. Examples are the Cobas 4800 
BRAF V600 Mutation Test (Roche Molecular Systems Inc.) 
which detects the BRAF V600E mutation in formalin-fixed, 
paraffin-embedded (FFPE) human melanoma tissue and the 
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular 
Inc.), which detects rearrangements involving the ALK gene 
via fluorescence in situ hybridization (FISH) in FFPE tissue. 
However, limited access to serial tumor biopsies constitutes 
a major shortcoming in longitudinal molecular monitoring 
of targeted treatment. In addition, molecular diagnostics 
based on analysis of biopsied or surgically resected tumor 
tissue is hampered by sampling error. Many types of can-
cer, including melanoma, non-small cell lung cancer, and 
in particular glioma, have demonstrated to be of heteroge-
neous nature [156]. Glioma tissue heterogeneity may con-
found assessment of molecular markers such as EGFRvIII 
expression and MGMT promoter methylation. Such molecu-
lar diagnostic problems could be solved by minimally inva-
sive techniques, possibly via advanced imaging modalities 
[9, 172] or ‘liquid biopsies’ [40, 66, 72, 88, 129, 137, 155, 
168]. Additionally, liquid biopsies might allow for faster 
and more accurate tumor diagnosis of difficult-to-diagnose 
patients, e.g., patients presenting with a ring-enhancing 
lesion in the brain as measured by MR imaging that can be 
diagnosed as either a metastasized solid tumor or a primary 
brain tumor [26]. On top, molecular markers obtained via 
liquid biopsies may allow for repeated assessment of molec-
ular aberrations of the tumor and real-time treatment moni-
toring in patients with diffuse glioma.
Importantly, whereas pathologists in conjunction with 
clinical geneticists are in the midst of a transformation 
towards molecular cancer diagnostics, the field of blood-
based cancer analysis is still awaiting such a full transfor-
mation. Blood-based analysis, historically often positioned 
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at the departments of clinical chemistry and microbiology, 
may likely benefit from a repositioning within the medi-
cal disciplines involved. In practice, the optimal develop-
ment of diagnostics based on liquid biopsies—defined 
here as biofluids used for molecular diagnostics—will 
require next-level interdisciplinary action of clinical chem-
ists, clinical geneticists, microbiologists, and (molecular) 
pathologists, among others. In this review on liquid biop-
sies in patients with diffuse glioma, we provide a concise 
discussion of the current state of the art of five blood-based 
liquid biopsy biosources [plasma; serum; extracellular vesi-
cles; blood platelets (thrombocytes); circulating tumor cells 
(CTCs)], followed by a more elaborate discussion regard-
ing the potential of detecting circulating proteins, circulat-
ing nucleic acids (DNA, different forms of RNA) and of 
circulating tumor cells.
Biosources in liquid biopsies for molecular markers
Plasma and serum are collected from whole blood and 
are the most studied biosources for molecular markers 
(Fig. 1). Circulating tumor DNA (ctDNA) and microR-
NAs (miRNAs) are relatively stable in plasma and serum, 
as opposed to messenger (mRNA) that is easily degraded. 
Nevertheless, within several hours of release ctDNA is 
removed from the circulation by the liver and the kidneys 
[149]. Plasma and serum also contain extracellular vesi-
cles (EVs), which are small lipid membrane-bound satch-
els expelled by cells to mediate cell-to-cell communication 
and containing a wide collection of nucleic acids, lipids, 
and proteins [4, 43, 54, 155]. The physical structure of 
EVs protects nucleic acids from degradation by circulating 
nucleases [92, 155]. Indeed, isolation of RNA from serum-
derived EVs from patients with glioblastoma can yield a 
60× greater concentration of RNA compared to free-circu-
lating RNA from whole blood, plasma or serum [30], which 
makes EVs a promising source for circulating RNA bio-
markers. Complementary, circulating platelets are supplied 
by gliomas with tumor-derived EVs and contain tumor-
derived RNA [116]. Interestingly, the majority of EVs 
circulating in blood are also derived from platelets, sug-
gesting that platelets efficiently sequester and release EVs 
[134, 187]. Similar to EVs, internalized nucleic acids in 
Fig. 1  Overview of biomarker 
release, collection and assess-
ment. In (glial) tumors, both 
neoplastic cells and the tumor-
microenvironment release 
biomolecules in the circulation, 
either as circulating proteins 
(CP), circulating nucleic acids 
(CNA), or even complete 
circulating tumor cells (CTC). 
Blood plasma and serum are 
a source of circulating tumor 
DNA (ctDNA), circulating 
microRNAs (miRNAs) and 
circulating proteins. From 
whole blood, also extracellular 
vesicles (EVs), platelets (which 
internalize EVs) or complete 
CTCs can be isolated and used 
as potential biosources. These 
five biosources provide proteins, 
miRNAs, messenger RNAs 
(mRNA) non-coding RNAs 
(ncRNA) and ctDNA biomol-
ecules (see separate lower right 
table). Of note, in the lower 
right table only biomolecules 
that were already identified 
in the particular biosources in 
patients with diffuse glioma are 
marked. These biomolecules 
and cells can be collected from 
a routinely obtained peripheral 
blood sample and used for fur-
ther analyses in the laboratory
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platelets are protected from endogenous nucleases. Finally, 
CTCs, although widely studied for many solid tumors [87], 
were only recently detected in the blood of patients with 
glioma [104, 113, 162]. The origin of circulating biomark-
ers, either directly derived from glioma cells or indirectly 
released by cells in the tumor microenvironment, such as 
inflammatory, endothelial and stromal cells, or at more dis-
tant sites like the bone marrow, is not known for all molec-
ular biomarkers. Obviously, EGFRvIII and IDH mutant 
proteins or nucleic acids are released primarily by glioma 
cells, whereas potential biomarkers such as VEGF can be 
derived from multiple cell types. Also, both active secretion 
and passive release are possible routes for biomolecules to 
enter the circulation, e.g., via apoptotic or necrotic tumor or 
tumor-infiltrating cells [40, 149]. In this review, cerebrospi-
nal fluid (CSF) and urine are more marginally discussed as 
alternative biosources. As brain tumors are located intracra-
nially and the brain is surrounded by CSF, this fluid may be 
an additional attractive liquid biopsy biosource for glioma 
[132]. Several studies have shown the suitability of detect-
ing tumor-derived circulating nucleic acids [1, 10, 32, 132] 
and proteins [51, 53, 69, 83, 89, 90, 97, 115, 124, 142–144, 
148, 153, 189, 191, 194] in CSF. However, collecting CSF 
is a more invasive, and burdensome procedure that harbors 
risks, particularly the risk of brain herniation in subjects 
with intracranial space-occupying lesions. Biomarkers can 
be either directly released into the CSF or accumulate via 
the brain interstitial fluid and perivascular drainage system 
into the cerebrospinal fluid [23, 41, 75]. Possibly, potential 
biomarkers in CSF also end up like a ‘sink effect’ in the 
circulating blood [92].
The individual candidate biomarkers are discussed 
below in order of biomarker class, i.e., circulating proteins 
(CPs) or circulating nucleic acids (CNAs), and further sub-
classified according to biomarker type (diagnostic, prog-
nostic, predictive, monitoring). The biofluids, biosources, 
biomarker classes, and biomarker types suitable for liquid 
biopsies are summarized in Fig. 1. Moreover, we discuss 
current and future issues which may benefit from assess-
ment of circulating biomarkers and lead to improved clini-
cal care for patients with diffuse glioma.
Circulating proteins (CPs)
Under several pathological conditions including cancer, the 
secretion, shedding and/or loss of proteins can become dif-
ferentially regulated and subsequently result in increased or 
decreased levels of circulating proteins (CP) in blood, urine 
and/or CSF [17, 185]. The majority of studies concerning 
protein markers is performed on blood [number of stud-
ies (n) = 29 for plasma, and n = 40 for serum], although 
also CSF (n = 19) and urine (n = 4) have been reported 
as biosources for CPs in these patients as well. In blood-
based glioma biomarker discovery studies, proteins are so 
far the most extensively studied biomolecules (summarized 
in Supplementary Table 1). The majority of these reports is 
of an exploratory nature and most molecules have not yet 
been evaluated in large clinical trials.
Diagnostic circulating protein markers
First attempts to detect CP markers in blood of patients 
with glioma resulted predominantly in the identification 
of markers differentially expressed between patients and 
healthy controls. Plasma- and serum-derived protein mark-
ers—such as immunosuppressive acidic protein, alpha-1 
acidic glycoprotein and alpha-1 antitrypsin, the glycopro-
tein fibronectin, and the endothelial cell-derived thrombo-
modulin-1—were the first proteins to be found elevated in 
the blood of patients with glioma [84, 110, 141, 145], fol-
lowed by protein markers related to angiogenesis in glio-
mas. The serum and plasma protein levels of the marker 
VEGF have often been reported as significantly increased 
in patients with glioma compared to healthy controls [2, 28, 
37, 128, 131], and even higher in patients with metastatic 
brain lesions [71, 128]. Soluble VEGFR-1 (sVEGFR-1), 
but not sVEGFR-2, -3, and basic fibroblast growth factor 
(bFGF, alternatively known as FGF-2), have been reported 
to be increased in pre-operatively collected serum samples 
from newly diagnosed glioblastoma patients [39, 131]. 
Also, markers involved in tumor cell invasion and remod-
eling of extracellular matrix, such as matrix metalloprotein-
ases (MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs), were identified as potential diagnostic CP bio-
markers. Increased levels of MMP-2 and 9 were observed 
in CSF of high-grade glioma patients [51], and a larger 
study confirmed increased plasma levels of MMP-9 and 
TIMP-1 in patients with both grade II and IV glioma com-
pared to healthy controls [95]. Surprisingly, however, in 
this study no difference was observed in the plasma protein 
levels of MMP-9 and TIMP-1 of grade III glioma patients 
as compared to healthy controls. Serum and plasma levels 
of TIMP-1 allowed the discrimination of grade IV from 
lower grade gliomas, and were confirmed in two addi-
tional studies [39, 95, 155, 157]. Furthermore, glial fibril-
lary acidic protein (GFAP) was suggested to have diagnos-
tic value [24, 68, 73, 80, 102]. An increase of circulating 
GFAP levels was observed in pre-operatively collected 
samples from grade III and IV glioma patients in both 
serum and plasma [68, 73]. Also in a subset of patients with 
oligodendroglial tumors, high levels of GFAP were found 
in plasma, implying that circulating GFAP is not specific 
for high-grade malignant astrocytic neoplasms [68]. Of 
interest, in patients with multiple sclerosis or a metastatic 
brain lesion, plasma GFAP levels were found to be within 
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the reference range [73, 102]. Plasma GFAP may, together 
with plasma placental growth factor (PlGF), differentiate 
between radiologically suspected high-grade glioma and 
brain metastases [73]. Obviously, the fact that not only 
GFAP, but also other markers such as brain-derived neuro-
trophic factor (BDNF) and S100 calcium binding protein B 
(S100B), can be detected in the circulation of healthy con-
trols negatively influences the specificity of such protein 
markers for detection of disease processes [91]. Finally, 
urine protein levels of 2-hydroxyglutarate (2-HG) may aid 
in distinguishing IDH1 mutant glioma patients from those 
with IDH1 wild-type glioma [98]. Assessment of the 2-HG 
metabolite in pre-operatively collected serum samples did 
not allow for such discrimination [27]. Potential diagnostic 
value has also been reported for serum and/or plasma lev-
els of EGFR protein [127, 151], transforming growth factor 
beta (TGFb) [147], tumor necrosis factor alpha (TNFa) [2, 
28, 59, 131], interleukin 2 (IL-2) and its receptor [59, 192], 
Chitinase-3-like protein 1 (CHI3L1, also known as YKL-
40) [15, 167], S100B [73, 102, 175], neural cell adhesion 
molecule (NCAM) [171], neuropeptide Y (NPY) [73] and 
BDNF [73].
Prognostic circulating protein biomarkers
CP markers with prognostic value can be subdivided in 
two subgroups; tumor-related markers and markers asso-
ciated with endogenous systemic stress responses. The 
glioma-related serum and plasma markers YKL-40, osteo-
pontin (OPN) and the extracellular domain of EGFR were 
described to be inversely correlated with overall survival 
[15, 63, 67, 77, 127, 157]. Interestingly, increased serum 
levels of YKL-40 1 week after surgery and during follow-
up of glioma patients, both newly diagnosed and recur-
rent, were associated with increased risk of death, also 
when adjusted for age, Karnofsky performance scale (KPS) 
and extent of surgical resection [15, 67, 77]. Furthermore, 
serum levels of YKL-40 appeared to be relatively stable 
over time [167]. In patients with recurrent glioblastoma 
prior to treatment with a combination of the monoclonal 
antibody bevacizumab and the topoisomerase 1 inhibitor 
irinotecan, elevated plasma levels of MMP-2 and decreased 
plasma levels of MMP-9 were associated with increased 
overall survival (OS) [165]. In addition, many CP mark-
ers implicated in tumor angiogenesis are associated with 
the survival of patients with glioma. The plasma levels 
of IGFBP-2 and VEGF, the serum level of plasminogen 
activator inhibitor-1 (PAI-1), and the CSF protein lev-
els of hepatocyte growth factor (HGF), bFGF and VEGF 
were inversely associated with progression-free survival 
(PFS) and OS [49, 76, 94, 124, 188]. Elevated levels of 
these CP markers may reflect more aggressive tumors 
with extensive angiogenesis and subsequent leakage of 
tumor-derived molecules into the circulation. Furthermore, 
a stress response of the body, represented by elevated lev-
els of C-reactive protein (CRP), the S100B protein, d-dimer 
and several heat shock proteins, has been associated with 
worse prognosis [65, 110, 158, 175]. Altogether, the most 
promising prognostic CP marker for glioma patients thus 
far seems to be serum YKL-40 protein.
Predictive circulating protein markers
Predictive CP markers in patients with glioma may facili-
tate therapy selection without the need for invasive tumor 
tissue biopsies. So far, predictive CP markers for patients 
with diffuse glioma were mainly identified in phase I and 
II clinical trials testing the effect of anti-angiogenic treat-
ments (esp. bevacizumab). Nevertheless, also for other 
established therapy regimens in patients with glioma, like 
TMZ treatment (see also CNAs), predictive CP mark-
ers might contribute to patient stratification. Tabouret 
et al. [165] reported that increased plasma protein levels 
of MMP-2 (>227.5 ng/ml) prior to combinatorial beva-
cizumab and irinotecan treatment were associated with 
higher probability of response to treatment (83 % com-
pared to 15 %). Decreased plasma protein levels of MMP-9 
(<235 ng/ml) were considered to be related to treatment 
response, although this was not confirmed in an additional 
patient cohort [165]. In a relatively small study (n = 10 
recurrent glioblastoma patients), Chinnaiyan et al. [34] 
identified IGFBP-5 as a possible predictive protein marker 
for combined treatment with bevacizumab, HDAC inhibi-
tor vorinostat, and irinotecan. Finally, non-responders to a 
combination therapy with bevacizumab and irinotecan had 
significantly increased plasma levels of IL-8 and G-CSF 
prior to start of the treatment as compared to responders 
[46].
Monitoring circulating protein markers
Circulating protein markers in patients with glioma that 
can be potentially employed to monitor the efficacy of a 
particular treatment are gaining attention. The individual 
biological tumor properties and complex tissue alterations 
induced by different anti-tumor treatments are not properly 
assessed with current MR imaging protocols and response 
criteria [181]. These criteria consider in particular two of 
the imaging characteristics: contrast uptake and alteration 
of the T2-weighted signal. Both characteristics, however, 
do not always properly reflect tumor behavior. Contrast 
enhancement indicates disruption of the blood–brain bar-
rier related to tumor progression, but anti-angiogenic treat-
ment reduces the number and permeability of tumor blood 
vessels and decreases the amount of MR contrast agent in 
the tumor, resulting in potential misinterpretation of tumor 
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regression (pseudo-response), whereas combined chem-
oirradiation may lead to temporarily increased contrast 
enhancement, erroneously interpreted as tumor progression 
(pseudo-progression). T2-weighted signal changes suggest 
diffuse infiltrative tumor progression, but might also be 
caused by tumor- or treatment-induced edema, resulting in 
misinterpretation as progression [163].
Blood-based biomarkers may allow circumvention of 
problematic pseudo-responses upon anti-angiogenesis 
treatment and pseudo-progression upon chemoradiother-
apy treatment. Two studies that together included approxi-
mately 90 recurrent glioblastoma patients treated with 
bevacizumab plus irinotecan demonstrated that a decreased 
plasma protein level of VEGF, measured, respectively, 
eight weeks and 15 days after the start of the treatment, 
was associated with improved PFS and OS [46, 165]. In 
addition, decreased plasma protein levels of MMP-9 were 
associated with prolonged PFS and OS, whereas changes 
in the plasma protein levels of bFGF, SDF-1a, PlGF or 
VEGFR-2 were not associated with the effect of beva-
cizumab [165]. Unfortunately, baseline levels of VEGF 
was not associated with PFS in the larger AVAglio study 
(n = 571) [139]. Treatment responses of recurrent glioblas-
toma patients (n = 26) treated with the VEGF and PlGF 
sequestering drug aflibercept were not associated with sig-
nificant changes in plasma protein levels of VEGF, despite 
initial reduction of this marker in plasma and subsequent 
increases of circulating VEGF and PlGF after 2 weeks 
of treatment [62]. Nevertheless, increased expression of 
MMP-9 and certain chemokines (e.g., MCTP3, MIF, IP-10) 
was correlated with tumor progression after 28 days of 
treatment, and may serve as putative CP monitoring mark-
ers for aflibercept treatment.
Multiple studies assessing the efficacy of the pan-
VEGFR RTK inhibitor cediranib in both newly diagnosed 
and recurrent glioblastoma patients have included circulat-
ing biomarker discovery as an important component of the 
clinical trials. CPs were assessed in plasma and urine sam-
ples at different time points during treatment. Most notably, 
in recurrent glioblastoma patients, increased plasma pro-
tein levels of PlGF and IL-8 and decreased levels of bFGF 
and sTie-2 proteins were associated with partial radiologi-
cal responses, whereas increased plasma protein levels of 
sVEGFR-1, sTie-2 and SDF-1a and decreased levels of 
PlGF correlated with radiological progression. Further-
more, a trend was observed between bFGF and SDF-1a 
levels, tumor vessel size and tumor progression. Increased 
plasma levels of PlGF and bFGF measured one day after 
start of treatment for recurrent glioblastoma correlated with 
improved OS. Increased plasma levels of MMP-2 and urine 
levels of MMP-9 measured within 1 day after the start of 
treatment were associated with shorter OS and PFS, respec-
tively [11, 13]. In a trial assessing the efficacy of cediranib 
combined with standard treatment in newly diagnosed 
glioblastoma patients, increased plasma protein levels of 
sVEGFR-1 and IL-8, after, respectively, 29 and 48 days of 
treatment, were associated with reduced PFS [12]. MMP-9 
and sVEGFR-1 were identified in plasma as potential CP 
monitoring markers for a combination therapy of TMZ plus 
the VEGF and PDGFR inhibitor vatalanib [56].
Circulating nucleic acids (CNA)
Tumor-associated CNAs have been identified in the blood 
of patients with several types of cancer as early as 1977 
[50, 93], and may be suitable for diagnosis and monitor-
ing of tumor treatment [44, 114]. Several classes of CNAs 
are detected; ctDNA including methylated DNA, mRNA, 
and small RNAs including miRNAs and transfer RNAs 
(tRNAs) (Fig. 1). Tumor-derived nucleic acids can be 
detected as cell-free entities, attached to lipid or protein 
structures, or as content of circulating EVs or blood plate-
lets [38, 40, 43, 116, 150, 155]. Of note, in a large study in 
which the presence of detectable ctDNA in several types of 
cancer was assessed only in a minority (10 %) of patients 
with glioma ctDNA was detected [16], indicating that the 
use of this biomarker in this patient category is challenging. 
In this section, we summarize the literature on CNAs in 
patients with diffuse glioma, while Supplementary Table 2 
provides a comprehensive overview of relevant studies on 
this topic.
Diagnostic circulating nucleic acid biomarkers
So far, most diagnostic CNA markers in patients with gli-
oma were detected by miRNA profiling. Circulating miR-
NAs exhibit great stability in plasma and serum [33, 111], 
and their involvement in glioma pathogenesis has been 
extensively studied [112]. Several groups reported that 
differential expression of multiple miRNA sets in plasma, 
serum and blood cells distinguishes glioma patients from 
healthy controls [74, 103, 136, 152, 178, 190]. Unfor-
tunately, the overlap between studies regarding plasma 
miRNA biomarkers is limited, and further validation is 
needed. Two studies compared the content of small RNAs 
in serum-derived EVs from patients with glioblastoma and 
healthy controls. Interestingly, RNA isolated from EVs 
appeared to be enriched for small RNAs in both healthy 
individuals and glioblastoma patients [117]. Based on the 
small RNA content, patients with glioblastoma could be 
distinguished from healthy controls [106]. Of note, it was 
recently reported that miRNAs are post-transcription-
ally modified by the enzymatic addition of nucleotides at 
the 3′-end of the mature miRNA, thereby affecting their 
release by tumor cells [86]. Hence, for miRNA biomarker 
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studies in liquid biopsies it is of crucial importance to take 
into account the presence of such non-templated nucleo-
tide additions, possibly changing the CNA biomarker 
landscape. Other serum CNA markers such as loss of het-
erozygosity (LOH) of chromosome arms 1p, 19q and 10q, 
and methylation of p16/INK4a and RASSF1A were also 
associated with the ability to identify patients with par-
ticular types of brain tumors [92, 105, 176]. Additionally, 
measurements of methylation of circulating ALU repeat 
sequences (i.e., non-coding transposable elements inte-
grated in the human genome) in plasma demonstrated a 
significant correlation with tissue methylation and were 
reported to allow for distinguishing low- from high-grade 
glioma patients and healthy controls [31].
Prognostic circulating nucleic acid biomarkers
The number of prognostic CNA biomarkers identified 
in patients with diffuse glioma so far is limited. Liu et al. 
[96] identified an association between hypermethylation of 
both MGMT and thrombospondin-1 in plasma of grade II 
and grade IV glioma patients and, counter-intuitively, an 
inferior OS. However, the authors do not provide detailed 
information on treatment regimens that may well have had 
an impact on the outcome of the included patients. In con-
trast, in a prospective study collecting longitudinal plasma 
samples from grade II–IV glioma patients, presence of 
methylated MGMT was associated with increased PFS 
and OS [48]. Finally, both increased plasma levels of miR-
454-3p and hypomethylation of ALU repeat elements in 
serum were reported to be associated with worse prognosis 
[31, 152].
Predictive circulating nucleic acid biomarkers
Predictive properties of CNA biomarkers were predomi-
nantly studied for MGMT promoter methylation, EGFRvIII 
and the IDH1 R132H mutation. In this respect, EGFRvIII 
and IDH1 R132H are regarded as companion diagnostic bio-
markers. Patients with methylated MGMT detected in serum 
ctDNA showed a significantly higher response to BCNU 
treatment, measured by imaging and clinical examination, 
compared to non-methylated MGMT ctDNA [8]. How-
ever, methylated MGMT in serum did not predict treatment 
response to the combination therapy of TMZ and cispl-
atin, possibly due to the inhibitory effect of cisplatin on the 
MGMT enzyme [8, 21, 177]. Of note, these authors demon-
strated a sensitivity of ~50–80 % and a specificity of 100 % 
of methylated MGMT in serum and plasma compared to the 
result of MGMT analysis of the tumor tissue (Supplemen-
tary Table 3). Detection of specific mutations and deletion 
variants is of interest for integration of blood-based markers 
in clinical trials, e.g., for the EGFRvIII-targeted immuno-
therapy using rindopepimut (CDX-110). Rindopepimut 
is currently being evaluated in a phase III study for newly 
diagnosed glioblastoma patients (ACT IV) and in a phase 
II study for recurrent glioblastoma patients in combination 
with GM-CSF (ReACT) [6]. Recently, EGFRvIII RNA 
has been detected in serum EVs of glioma patients [155] 
and EGFRvIII ctDNA in plasma [140]. Moreover, Nilsson 
et al. [116] documented efficient uptake of EVs by blood 
platelets and detected EGFRvIII mRNA in these elements. 
Based on this information, diagnosis of EGFRvIII through 
liquid biopsies could allow for patient selection for specific 
anti-EGFRvIII treatment during clinical follow-up and pos-
sibly also for treatment monitoring. In addition, blood-based 
diagnosis of EGFRvIII may help to circumvent the possible 
underdiagnosis of heterogeneously expressed EGFRvIII in 
tumor tissue. Another genetic event of particular interest for 
use in companion diagnostics is the IDH1 R132H mutation 
[121, 135]. Although the IDH1 mutation was detected in 
CSF EVs of glioblastoma patients, it could not be detected 
in serum EVs of the same patients [30, 32]. Boissellier et al. 
[19] detected mutant IDH1 ctDNA with a sensitivity of 
60 % and a specificity of 100 %. In this study, detection of 
mutant IDH1 in LGG patients depended on tumor volume 
and in high-grade glioma patients on the presence of con-
trast enhancement as visualized by MR imaging.
Monitoring circulating nucleic acid biomarkers
EGFRvIII ctDNA, or EGFRvIII mRNA in EVs or platelets 
may be considered as a monitoring marker in studies of 
therapeutics specifically or indirectly targeting EGFRvIII. 
The loss of ctDNA EGFRvIII was noted in two patients 
following gross total resection of the tumor [140]. Fur-
thermore, assessment of the MGMT methylation status in 
blood during TMZ treatment revealed that the cumulative 
incidence of unmethylated MGMT promoter, measured in 
longitudinal samples from 58 patients with diffuse glioma, 
increased from 58 % at the start of TMZ treatment to 92 % 
after 12 months of follow-up. This may be explained by the 
selection and outgrowth of tumor subclones with unmethyl-
ated MGMT promoter during TMZ treatment [48]. Circu-
lating miRNA markers, which raised to reference levels of 
healthy controls following surgery and radio-chemotherapy 
of patients with diffuse glioma, may also have monitor-
ing value [178, 190]. Furthermore, the significantly higher 
levels of miR-23, -150, -197 and -548b-5p were reported 
to occur in serum of patients with radiation necrosis/astro-
gliosis (n = 11) rather than in patients with diffuse glioma 
and may be of value to distinguish tumor progression from 
pseudo-progression after radiation (AUC: 0.95 95 % CI 
0.902–0.998) [190].
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Circulating tumor cells (CTCs)
Circulating tumor cells are neoplastic cells that are detected 
in the circulation, and that can potentially be used as bio-
marker biosource [120]. CTCs are isolated through sophis-
ticated techniques that separate CTCs from other blood 
cells by their unique physical and biological properties 
[3]. While previous attempts to isolate glioma CTCs were 
unsuccessful [18, 107], three independent research groups 
recently reported isolation of CTCs from glioma patients 
using three different novel isolation and detection methods 
(see also Supplemental Table 2). First, fluorescence immu-
nocytochemistry was performed on purified mononuclear 
cells for GFAP-positive, CD45-negative CTCs. In 28 out 
of 141 glioblastoma patients, CTCs were identified, while 
these CTCs were not detected in patients with brain metas-
tases. Following surgery, no significant difference was 
observed in CTC counts before, during or after surgery and 
no correlation between CTC counts and clinical outcome 
was found [113]. Second, a telomerase-responsive adeno-
viral vector encoding a fluorescent reporter was employed 
to detect hTERT-positive cells, resulting in detection of 
CTCs in 8 out of 11 glioblastoma patients analyzed before 
radiotherapy and TMZ treatment. In two patients, the 
quantitation of CTCs allowed the separation of pseudo-
progression from tumor progression as measured by MR 
imaging [104]. Finally, Sullivan et al. applied a CTC-iChip, 
which allows the removal of anucleated cells and depletion 
of leukocytes from the remaining cell pellet via magneti-
cally tagged antibodies (CD16, CD45), yielding untagged 
and un-manipulated CTCs. Next, fluorescent probes target-
ing five markers for glioma cells (termed STEAM: Sox2, 
Tubulin beta-3, EGFR, A2B5, c-Met) were introduced. In 
13 out of 33 glioblastoma patients, CTCs were detected. 
CTCs were enriched for transcripts associated with a mes-
enchymal glioblastoma signature. Interestingly, the expres-
sion levels of these transcripts were not always in accord-
ance with the signature that was detected in the tissue of 
the corresponding glial tumor, suggesting a preference of 
a particular subset of tumor cells (not necessarily being the 
predominant tumor cell population) for entering the circu-
lation. Moreover, no additional correlations between CTCs 
and clinical parameters were observed [162]. Of note, a 
potential role for circulating endothelial (precursor) cells 
and T-lymphocytes (esp. T-regulatory cells) as diagnostic, 
prognostic, predictive, and monitoring markers in patients 
with diffuse glioma has been suggested [5, 13, 37, 42, 
47, 60, 61, 128, 130, 184, 193]. In addition, immune cells 
release a broad range of CPs that could be of interest in 
this respect. The diagnostic value of immune cell-derived 
CNAs remains to be investigated [187]. In conclusion, suc-
cessful isolation of CTCs from the blood of glioma patients 
was demonstrated using different techniques. In 20–73 % 
of high-grade glioma patients CTCs were detected. It 
remains to be evaluated whether glioma CTCs fully repre-
sent the heterogeneous tumor cell population, and what the 
diagnostic, prognostic, predictive and monitoring potential 
of CTCs is in patients with diffuse gliomas.
Conclusions and future directions
Biomarkers can be isolated from biofluids such as blood, 
and also CSF and urine. There is a plethora of small and 
mainly explorative studies describing blood-based bio-
markers in patients with diffuse glioma. The use of different 
techniques and methodologies for detection of the biomark-
ers and the mainly retrospective nature of the studies com-
plicates drawing solid conclusions. In Fig. 2, we provide an 
overview of the biomarkers in liquid biopsies reported to 
be of potential relevance for diagnosis and/or management 
of patients with diffuse glioma. All blood-based biomarkers 
reported until now need further validation. Meanwhile, in 
the near future assessment of blood-based biomarkers can 
be expected to improve patient stratification and monitor-
ing. Ideally, phase I trials should already include biomarker 
discovery, with further validation of potential biomarkers 
in phase II and III trials, including determination of proper 
cutoff values for biomarkers [77]. Furthermore, additional 
studies are needed that uncover potential circulating bio-
markers accompanying MR imaging during clinical follow-
up for, e.g., LGG patients. Finally, markers suggested in 
this review such as PlGF and GFAP have to be evaluated 
for its diagnostic potential for difficult-to-diagnose patients 
(e.g., in the differential diagnosis of metastasis versus pri-
mary brain tumor). The evaluation of biomarker panels 
[39, 45, 151], instead of sole biomarkers, using standard-
ized detection methods, could be useful for further enhanc-
ing the sensitivity and specificity of blood tests [167]. This 
could be accompanied by a two or more steps decision 
tree algorithm as was recently shown for three diagnostic 
CP markers (GFAP, IGFBP-2, and YKL-40) [52]. The use 
of “omic-approaches” is likely to boost such a biomarker 
panel analysis [20, 55, 82, 83, 89, 97, 115, 148, 194].
The most extensively studied CP biomarkers are circu-
lating angiogenesis-related proteins. While such proteins 
may indeed be useful as prognostic and monitoring bio-
markers for anti-angiogenic therapies, a robust biomarker 
for the monitoring of bevacizumab treatment (i.e., the most 
widely applied anti-angiogenic therapy to date) has not yet 
been reported. Additionally, the discovery of tumor-derived 
ctDNA, circulating miRNAs, EVs and platelets sequester-
ing tumor-derived EGFRvIII do point at the possibility 
to use blood as a source of CNA biomarkers in patients 
with diffuse glioma. An advantage of CNA biomarkers is 
the possibility to detect genetic aberrations such as IDH1 
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mutations and EGFRvIII, which are of special interest as 
predictive markers for current clinical trials. Acknowledg-
ing that ctDNA so far was measurable in only a minority 
of patients with a diffuse glioma, detection of RNA might 
be more sensitive as compared to ctDNA, especially when 
analyzing the fraction of EVs or blood platelet in which 
RNAs are protected from circulating nucleases [16]. 
Assessment of circulating biomarkers may be of particular 
value for molecular markers that are known to be heteroge-
neously distributed (with a danger of sampling error) such 
as EGFRvIII. Also, IDH1 mutations detected in ctDNA and 
EVs isolated from CSF may provide a way for non-invasive 
assessment of diagnostic and prognostic properties.
Thus far, many different tumor-related and tumor-
derived markers have been identified in the circulation of 
patients with glioma that might attribute as specific bio-
markers. Rational selection of the most promising biomark-
ers for incorporation in clinical trials is warranted, with 
literature mining as an important tool for such a selection. 
Potential biomarkers extracted from the present review of 
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Fig. 2  Example of molecular biomarker assessment using liquid 
biopsy in patients with low- and high-grade glioma. Central black 
line depicts a simplified timeline of clinical events for patients with 
low- or high-grade glioma (LGG versus HGG). A pre-surgical work-
ing diagnosis (based on esp. clinical and radiological investiga-
tions) leads to surgery (biopsy or resection of tumor tissue). After a 
pathological diagnosis is made, most glioma patients receive ‘con-
ventional chemo- and/or radiotherapy’ (CCR), but in LGG patients 
clinical monitoring is also (still) common practice. Especially after 
failure of CCR, experimental therapy (ET) can be administered. 
Above the timeline, imaging (available during the entire follow-up 
of the patient) and the most widely accepted molecular biomarkers 
analyzed in diffuse glioma tissue samples are depicted. Tumor tissue 
samples are obtained during surgery, and might again be obtained at 
the moment of tumor progression (dashed line box). The boxes below 
the timeline show promising blood-based biomarkers as deduced 
from this review and grouped according to their potential meaning 
(diagnostic, prognostic, predictive, monitoring) in different phases 
of the disease process. The blood-based biomarkers mentioned here 
are selected based on the number of studies measuring the biomarker 
and the number of patients included in these studies. Each charac-
ter indicates for which group of diffuse glioma patients or treatment 
the biomarker might be suitable. #Predictive and monitoring markers 
selected for CCR regimens (temozolomide and procarbazine–lomus-
tine–vincristine treatment). §Predictive and monitoring markers 
selected for experimental therapies (see also individual characters). 
Characters accompanying biomarkers: a primary GBM (pGBM) 
vs. healthy controls, b pGBM vs. LGG, c LGG vs. healthy control, 
d secondary GBM vs pGBM, e primary diffuse glioma vs. metas-
tasis to the brain, f HGG, g LGG, h surgery, i temozolomide treat-
ment, j chemoradiotherapy, k bevacizumab and irinotecan treatment, 
l cediranib treatment, m aflibercept treatment, n rindopepimut (anti-
EGFRvIII) treatment, o IDH1 mutant inhibitor AGI-5198
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the literature for different stages of clinical management 
of patients with diffuse gliomas are summarized in Fig. 2. 
Obviously, regular and systematic evaluation of promis-
ing blood-based biomarkers, preferable on an international 
level via research communities such as the EORTC, would 
improve the assessment of their clinical value. Systematic 
collection of blood samples for future biomarker discov-
ery and the establishment of blood biobanks, also outside 
clinical trails, would be very helpful in this respect. Ide-
ally, such samples would be collected both prior to treat-
ment (to allow for identification of diagnostic, prognostic 
and predictive biomarkers) as well as during therapy, the 
latter in particular situations in which robust predictive and 
monitoring biomarkers are still lacking (e.g., bevacizumab 
treatment).
Blood-based liquid biopsies are of interest for the longi-
tudinal monitoring of tumor activity and therapy response. 
Depending on the blood fraction (i.e., serum or plasma), 
levels of CPs, CNAs, and possibly CTCs may vary consid-
erably. Some markers have demonstrated biomarker value 
in plasma, whereas others were only of potential value in 
serum [188]. Also, used assays and methodologies for 
detection of CPs, (modified) CNAs and CTCs, each with its 
own strengths and weaknesses, have to be critically consid-
ered, and standardization is required to be able to compare 
results between studies. Furthermore, storage conditions 
of liquid biopsy samples require consideration, as well as 
other variables such as disease state, histological tumor 
subtype, time of sampling, biosource and biomarker iso-
lation procedures, treatment regimen, assay reproducibil-
ity and sensitivity, protein half-life, biological processes, 
and normalization standards [25, 29, 39, 58, 73, 78, 79, 
138, 147, 153, 173, 186, 195]. Of note, the sequestration 
of several proteins and nucleic acids in platelets and the 
potential release of proteins and nucleic acids by platelets 
and immune cells during surgery and blood processing 
have to be taken into account [39, 85, 147]. Therefore, to 
thoroughly address these issues and to control for them, 
large standardized clinical studies, requiring specific study 
designs and well-validated molecular assays, will be of 
critical importance. Importantly, proper selection of a con-
trol group with a disease that is a meaningful differential 
diagnosis for glioma patients (e.g., tumor metastasis to the 
brain, primary CNS lymphoma, or infection) is important, 
especially in biomarker discovery [52, 126]. Conventional 
biomarker discovery using state-of-the-art next-generation 
DNA/RNA sequencing or protein quantifications can be 
expected to yield novel biomarkers correlated to a specific 
disease state.
In conclusion, the interest in liquid biopsies for the diag-
nostics of glioma is rapidly expanding. In recent years, 
many circulating biomarkers have been detected, evaluated 
and integrated in clinical trials. In the coming years, more 
large-scale biomarker discovery efforts in patients with dif-
fuse gliomas can be expected. Advances in the development 
of more sensitive assays allow for detection of low abundant 
(mutant) biomolecules in the circulation, further expanding 
the width of assessable biomarkers. Selection and validation 
of potential circulating biomarkers for patients with diffuse 
glioma is warranted. In the future, blood-based companion 
diagnostics may improve the drug discovery process for dif-
fuse glioma patients and further individualize the therapy 
of these patients. Within the coming decade, the ongoing 
research may well result in an interdisciplinary transforma-
tion of the classical blood-based analyses towards the rou-
tine use of liquid biopsies for molecular diagnostics, simi-
larly as we observed for tissue biopsies.
Acknowledgments Financial support was provided by European 
Research Council 336540, the Netherlands Organisation of Scien-
tific Research 91711366, the Dutch Cancer Society (grant project VU 
2013-5751), and STOPhersentumoren.nl.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle 
S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hoch-
berg FH, Van Meir EG, Carter BS, Chen CC (2013) MiR-21 in 
the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a 
platform for glioblastoma biomarker development. PLoS One 
8:e78115. doi:10.1371/journal.pone.0078115
 2. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, 
Petrescu D, Teodoru M, Tanase CP (2013) Cytokine patterns 
in brain tumour progression. Mediators Inflamm 2013:979748. 
doi:10.1155/2013/979748
 3. Alix-Panabières C, Pantel K (2013) Circulating tumor cells: 
liquid biopsy of cancer. Clin Chem 59:110–118. doi:10.1373/
clinchem.2012.194258
 4. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha 
A, Rak J (2008) Intercellular transfer of the oncogenic receptor 
EGFRvIII by microvesicles derived from tumour cells. Nat Cell 
Biol 10:619–624. doi:10.1038/ncb1725
 5. El Andaloussi A, Lesniak MS (2006) An increase in CD4+ 
CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lym-
phocytes of human glioblastoma multiforme. Neuro Oncol 
8:234–243. doi:10.1215/15228517-2006-006
 6. Babu R, Adamson DC (2012) Rindopepimut: an evidence-based 
review of its therapeutic potential in the treatment of EGFRvIII-pos-
itive glioblastoma. Core Evid 7:93–103. doi:10.2147/CE.S29001
 7. Bailey P (1926) A classification of the tumors of the glioma 
group on a histogenetic basis with a correlated study of progno-
sis. Lippincott, Philadelphia
 8. Balaña C, Ramirez JL, Taron M, Roussos Y, Ariza A, Bal-
lester R, Sarries C, Mendez P, Sanchez JJ, Rosell R (2003) 
O6-methyl-guanine-DNA methyltransferase methylation 
in serum and tumor DNA predicts response to 1,3-bis(2-
chloroethyl)-1-nitrosourea but not to temozolamide plus cispl-
atin in glioblastoma multiforme. Clin Cancer Res 9:1461–1468
859Acta Neuropathol (2015) 129:849–865 
1 3
 9. Baldock AL, Yagle K, Born DE, Ahn S, Trister AD, Neal M, 
Johnston SK, Bridge CA, Basanta D, Scott J, Malone H, Sona-
bend AM, Canoll P, Mrugala MM, Rockhill JK, Rockne RC, 
Swanson KR (2014) Invasion and proliferation kinetics in 
enhancing gliomas predict IDH1 mutation status. Neuro Oncol 
16:779–786. doi:10.1093/neuonc/nou027
 10. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner 
H, Schmiegel W, Hahn S, Schroers R (2012) Identification of 
microRNAs in the cerebrospinal fluid as biomarker for the diag-
nosis of glioma. Neuro Oncol 14:29–33. doi:10.1093/neuonc/
nor169
 11. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin 
SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner 
T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, 
Moses MA, Ivy P, Sorensen AG, Wen PY et al (2010) Phase 
II study of cediranib, an oral pan-vascular endothelial growth 
factor receptor tyrosine kinase inhibitor, in patients with recur-
rent glioblastoma. J Clin Oncol 28:2817–2823. doi:10.1200/
JCO.2009.26.3988
 12. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-
Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho 
MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, 
Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR 
et al (2013) Improved tumor oxygenation and survival in glio-
blastoma patients who show increased blood perfusion after 
cediranib and chemoradiation. Proc Natl Acad Sci 110:19059–
19064. doi:10.1073/pnas.1318022110
 13. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda 
DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, 
Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis 
DN, Ivy P, Scadden DT, Benner T, Loeffler JS et al (2007) 
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, nor-
malizes tumor vasculature and alleviates edema in glioblastoma 
patients. Cancer Cell 11:83–95. doi:10.1016/j.ccr.2006.11.021
 14. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, 
Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, 
Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, 
Cahill DP (2014) IDH1 mutant malignant astrocytomas are 
more amenable to surgical resection and have a survival ben-
efit associated with maximal surgical resection. Neuro Oncol 
16:81–91. doi:10.1093/neuonc/not159
 15. Bernardi D, Padoan A, Ballin A, Sartori M, Manara R, Scienza 
R, Plebani M, Della Puppa A (2012) Serum YKL-40 following 
resection for cerebral glioblastoma. J Neurooncol 107:299–305. 
doi:10.1007/s11060-011-0762-7
 16. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal 
N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, 
Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher 
LA, Gallia GL, Gibbs P et al (2014) Detection of circulating 
tumor DNA in early- and late-stage human malignancies. Sci 
Transl Med 6:224ra24. doi:10.1126/scitranslmed.3007094
 17. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cer-
ebrospinal fluid and plasma biomarkers in Alzheimer disease. 
Nat Rev Neurol 6:131–144. doi:10.1038/nrneurol.2010.4
 18. Böhm C, Wassmann H, Paulus W (2003) No evidence of tumour 
cells in blood of patients with glioma. Mol Pathol 56:187–189
 19. Boisselier B, Gállego Pérez-Larraya J, Rossetto M, Labussière M, 
Ciccarino P, Marie Y, Delattre J-Y, Sanson M (2012) Detection of 
IDH1 mutation in the plasma of patients with glioma. Neurology 
79:1693–1698. doi:10.1212/WNL.0b013e31826e9b0a
 20. De Bont JM, den Boer ML, Reddingius RE, Jansen J, Passier 
M, van Schaik RHN, Kros JM, Sillevis Smitt PA, Luider TH, 
Pieters R (2006) Identification of apolipoprotein A-II in cer-
ebrospinal fluid of pediatric brain tumor patients by protein 
expression profiling. Clin Chem 52:1501–1509. doi:10.1373/
clinchem.2006.069294
 21. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, 
Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M 
(2004) First-line chemotherapy with cisplatin plus fractionated 
temozolomide in recurrent glioblastoma multiforme: a phase II 
study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J 
Clin Oncol 22:1598–1604. doi:10.1200/JCO.2004.11.019
 22. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noush-
mehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, 
Berman SH, Beroukhim R, Bernard B, Wu C-J, Genovese G, 
Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA 
et al (2013) The somatic genomic landscape of glioblastoma. 
Cell 155:462–477. doi:10.1016/j.cell.2013.09.034
 23. Brinker T, Stopa E, Morrison J, Klinge P (2014) A new look 
at cerebrospinal fluid circulation. Fluids Barriers CNS 11:10. 
doi:10.1186/2045-8118-11-10
 24. Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V 
(2007) Serum levels of glial fibrillary acidic protein correlate 
to tumour volume of high-grade gliomas. Acta Neurol Scand 
116:380–384. doi:10.1111/j.1600-0404.2007.00889.x
 25. Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki 
DL, Pike M, Laham RJ, Simons M, Chronos NA (2001) Phar-
macokinetics and pharmacodynamics of recombinant FGF-2 
in a phase I trial in coronary artery disease. J Clin Pharmacol 
41:378–385
 26. Campos S, Davey P, Hird A, Pressnail B, Bilbao J, Aviv RI, 
Symons S, Pirouzmand F, Sinclair E, Culleton S, Desa E, Goh 
P, Chow E (2009) Brain metastasis from an unknown primary, 
or primary brain tumour? A diagnostic dilemma. Curr Oncol 
16:62–66
 27. Capper D, Simon M, Langhans C-D, Okun JG, Tonn JC, Weller 
M, von Deimling A, Hartmann C (2012) 2-Hydroxyglutarate 
concentration in serum from patients with gliomas does not cor-
relate with IDH1/2 mutation status or tumor size. Int J Cancer 
131:766–768. doi:10.1002/ijc.26425
 28. Carlsson A, Persson O, Ingvarsson J, Widegren B, Salford L, 
Borrebaeck CAK, Wingren C (2010) Plasma proteome profiling 
reveals biomarker patterns associated with prognosis and ther-
apy selection in glioblastoma multiforme patients. Proteomics 
Clin Appl 4:591–602. doi:10.1002/prca.200900173
 29. Carson KA, Grossman SA, Fisher JD, Shaw EG (2007) Prog-
nostic factors for survival in adult patients with recurrent gli-
oma enrolled onto the new approaches to brain tumor therapy 
CNS consortium phase I and II clinical trials. J Clin Oncol 
25:2601–2606. doi:10.1200/JCO.2006.08.1661
 30. Chen C, Skog J, Hsu C-H, Lessard RT, Balaj L, Wurdinger T, 
Carter BS, Breakefield XO, Toner M, Irimia D (2010) Micro-
fluidic isolation and transcriptome analysis of serum microvesi-
cles. Lab Chip 10:505–511. doi:10.1039/b916199f
 31. Chen J, Gong M, Lu S, Liu F, Xia L, Nie D, Zou F, Shi J, Ju 
S, Zhao L, Zuo H, Qi J, Shi W (2013) Detection of serum 
Alu element hypomethylation for the diagnosis and prog-
nosis of glioma. J Mol Neurosci 50:368–375. doi:10.1007/
s12031-013-0014-8
 32. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, 
Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivara-
man S, Chen C, Wong ET, Carter BS, Hochberg FH, Breake-
field XO, Skog J (2013) BEAMing and droplet digital PCR 
analysis of mutant IDH1 mRNA in glioma patient serum and 
cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic 
Acids 2:e109. doi:10.1038/mtna.2013.28
 33. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, 
Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, 
Xiang Y, Xu C, Zheng P et al (2008) Characterization of micro-
RNAs in serum: a novel class of biomarkers for diagnosis of 
cancer and other diseases. Cell Res 18:997–1006. doi:10.1038/
cr.2008.282
860 Acta Neuropathol (2015) 129:849–865
1 3
 34. Chinnaiyan P, Chowdhary S, Potthast L, Prabhu A, Tsai Y-Y, 
Sarcar B, Kahali S, Brem S, Yu HM, Rojiani A, Murtagh R, Pan 
E (2012) Phase I trial of vorinostat combined with bevacizumab 
and CPT-11 in recurrent glioblastoma. Neuro Oncol 14:93–100. 
doi:10.1093/neuonc/nor187
 35. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishi-
kawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, 
Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Beva-
cizumab plus radiotherapy-temozolomide for newly diag-
nosed glioblastoma. N Engl J Med 370:709–722. doi:10.1056/
NEJMoa1308345
 36. Claes A, Idema AJ, Wesseling P (2007) Diffuse glioma growth: 
a guerilla war. Acta Neuropathol 114:443–458. doi:10.1007/
s00401-007-0293-7
 37. Corsini E, Ciusani E, Gaviani P, Silvani A, Canazza A, Bernardi 
G, Calatozzolo C, DiMeco F, Di Meco F, Salmaggi A (2012) 
Decrease in circulating endothelial progenitor cells in treated 
glioma patients. J Neurooncol 108:123–129. doi:10.1007/
s11060-012-0805-8
 38. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, 
Sood AK, Calin GA (2011) MicroRNAs in body fluids–the mix 
of hormones and biomarkers. Nat Rev Clin Oncol 8:467–477. 
doi:10.1038/nrclinonc.2011.76
 39. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, 
Aherne W, Pearson A, Bell BA, Zacharoulis S, Papadopoulos 
MC (2011) Serum angiogenic profile of patients with glioblas-
toma identifies distinct tumor subtypes and shows that TIMP-1 
is a prognostic factor. Neuro Oncol 13:99–108. doi:10.1093/
neuonc/noq170
 40. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) 
Liquid biopsy: monitoring cancer-genetics in the blood. Nat 
Rev Clin Oncol 10:472–484. doi:10.1038/nrclinonc.2013.110
 41. Cuddapah VA, Robel S, Watkins S, Sontheimer H (2014) A 
neurocentric perspective on glioma invasion. Nat Rev Neurosci 
15:455–465. doi:10.1038/nrn3765
 42. Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, 
Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, 
Bertolini F, Finocchiaro G, Eoli M (2013) Prognostic value of 
CD109+ circulating endothelial cells in recurrent glioblastomas 
treated with bevacizumab and irinotecan. PLoS One 8:e74345. 
doi:10.1371/journal.pone.0074345
 43. D’Souza-Schorey C, Clancy JW (2012) Tumor-derived 
microvesicles: shedding light on novel microenvironment 
modulators and prospective cancer biomarkers. Genes Dev 
26:1287–1299. doi:10.1101/gad.192351.112
 44. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin 
S-F, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan 
S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Cal-
das C, Rosenfeld N (2013) Analysis of circulating tumor DNA 
to monitor metastatic breast cancer. N Engl J Med 368:1199–
1209. doi:10.1056/NEJMoa1213261
 45. Elstner A, Stockhammer F, Nguyen-Dobinsky T-N, Nguyen 
QL, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein 
K, Picht T, Veelken J, Martuza RL, von Deimling A, Kurtz A 
(2011) Identification of diagnostic serum protein profiles of 
glioblastoma patients. J Neurooncol 102:71–80. doi:10.1007/
s11060-010-0284-8
 46. Eoli M, Di Stefano A, Aquino D, Scotti A, Anghileri E, Cup-
pini L, Prodi E, Finocchiaro G, Bruzzone MG (2013) MC13-
0072 Tumor perfusion during bevacizumab and irinotecan in 
recurrent glioblastoma: a multimodal approach. Eur J Cancer 
49:S32. doi:10.1016/S0959-8049(13)70179-5
 47. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, 
Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH 
(2006) Increased regulatory T-cell fraction amidst a dimin-
ished CD4 compartment explains cellular immune defects in 
patients with malignant glioma. Cancer Res 66:3294–3302. 
doi:10.1158/0008-5472.CAN-05-3773
 48. Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, 
Sacerdote C, Gillio-Tos A, De Marco L, Grasso C, Magis-
trello M, Tondat F, Rudà R, Cassoni P, Soffietti R, Merletti F 
(2014) MGMT promoter methylation in plasma of glioma 
patients receiving temozolomide. J Neurooncol 117:347–357. 
doi:10.1007/s11060-014-1395-4
 49. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loef-
fler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK 
(2000) Phase II trial of the antiangiogenic agent thalidomide 
in patients with recurrent high-grade gliomas. J Clin Oncol 
18:708–715
 50. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper 
F, Dawson S-J, Piskorz AM, Jimenez-Linan M, Bentley D, Had-
field J, May AP, Caldas C, Brenton JD, Rosenfeld N (2012) 
Noninvasive identification and monitoring of cancer mutations 
by targeted deep sequencing of plasma DNA. Sci Transl Med 
4:136ra68. doi:10.1126/scitranslmed.3003726
 51. Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G 
(1998) Specific matrix metalloproteinase profiles in the cer-
ebrospinal fluid correlated with the presence of malignant astro-
cytomas, brain metastases, and carcinomatous meningitis. Can-
cer 82:923–930
 52. Gállego Pérez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-
Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson 
M, Hoang-Xuan K, Delattre J-Y, Mallet A (2014) Diagnostic 
and prognostic value of preoperative combined GFAP, IGFBP-
2, and YKL-40 plasma levels in patients with glioblastoma. 
Cancer. doi:10.1002/cncr.28949
 53. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J (2010) 
Hepatocyte growth factor in cerebrospinal fluid is associated 
with mortality and recurrence of glioblastoma, and could be 
of prognostic value. J Neurooncol 97:347–351. doi:10.1007/
s11060-009-0037-8
 54. Garnier D, Jabado N, Rak J (2013) Extracellular vesicles as 
prospective carriers of oncogenic protein signatures in adult 
and paediatric brain tumours. Proteomics 13:1595–1607. 
doi:10.1002/pmic.201200360
 55. Gautam P, Nair SC, Gupta MK, Sharma R, Polisetty RV, Uppin 
MS, Sundaram C, Puligopu AK, Ankathi P, Purohit AK, Chan-
dak GR, Harsha HC, Sirdeshmukh R (2012) Proteins with 
altered levels in plasma from glioblastoma patients as revealed 
by iTRAQ-based quantitative proteomic analysis. PLoS One 
7:e46153. doi:10.1371/journal.pone.0046153
 56. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, 
Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT (2011) 
Phase I trial with biomarker studies of vatalanib (PTK787) 
in patients with newly diagnosed glioblastoma treated with 
enzyme inducing anti-epileptic drugs and standard radiation 
and temozolomide. J Neurooncol 103:325–332. doi:10.1007/
s11060-010-0390-7
 57. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal 
DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won 
M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, 
Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sul-
man EP et al (2014) A randomized trial of bevacizumab for 
newly diagnosed glioblastoma. N Engl J Med 370:699–708. 
doi:10.1056/NEJMoa1308573
 58. Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, 
Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, 
Lacombe D, van den Bent MJ (2012) New prognostic factors 
and calculators for outcome prediction in patients with recur-
rent glioblastoma: a pooled analysis of EORTC Brain Tumour 
Group phase I and II clinical trials. Eur J Cancer 48:1176–1184. 
doi:10.1016/j.ejca.2012.02.004
861Acta Neuropathol (2015) 129:849–865 
1 3
 59. Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos 
G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP (2010) 
Frequent abnormalities of the immune system in gliomas and 
correlation with the WHO grading system of malignancy. J Neu-
roimmunol 226:136–142. doi:10.1016/j.jneuroim.2010.05.027
 60. Gousias K, von Ruecker A, Voulgari P, Simon M (2013) Phenotypi-
cal analysis, relation to malignancy and prognostic relevance of 
ICOS+ T regulatory and dendritic cells in patients with gliomas. J 
Neuroimmunol 264:84–90. doi:10.1016/j.jneuroim.2013.09.001
 61. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, 
Gutin PH (2009) Surrogate markers predict angiogenic potential 
and survival in patients with glioblastoma multiforme. Neuro-
surgery 64:819–826. doi:10.1227/01.NEU.0000343742.06625.
DB (discussion 826–827)
 62. De Groot JF, Piao Y, Tran H, Gilbert M, Wu H-K, Liu J, Bekele 
BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis 
L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Hey-
mach JV (2011) Myeloid biomarkers associated with glioblas-
toma response to anti-VEGF therapy with aflibercept. Clin Can-
cer Res 17:4872–4881. doi:10.1158/1078-0432.CCR-11-0271
 63. Güttler A, Giebler M, Cuno P, Wichmann H, Keßler J, 
Ostheimer C, Söling A, Strauss C, Illert J, Kappler M, Vorder-
mark D, Bache M (2013) Osteopontin and splice variant expres-
sion level in human malignant glioma: radiobiologic effects and 
prognosis after radiotherapy. Radiother Oncol 108:535–540. 
doi:10.1016/j.radonc.2013.06.036
 64. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet 
N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, 
Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer 
RC, Stupp R (2005) MGMT gene silencing and benefit from 
temozolomide in glioblastoma. N Engl J Med 352:997–1003. 
doi:10.1056/NEJMoa043331
 65. Hoke M, Dieckmann K, Koppensteiner R, Schillinger M, 
Marosi C, Mlekusch W (2011) Prognostic value of plasma 
d-dimer levels in patients with glioblastoma multiforme—
results from a pilot study. Wien Klin Wochenschr 123:199–203. 
doi:10.1007/s00508-011-1556-9
 66. Holdhoff M, Yovino SG, Boadu O, Grossman SA (2013) 
Blood-based biomarkers for malignant gliomas. J Neurooncol 
113:345–352. doi:10.1007/s11060-013-1144-0
 67. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar 
MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland 
EC (2006) YKL-40 and matrix metalloproteinase-9 as potential 
serum biomarkers for patients with high-grade gliomas. Clin Can-
cer Res 12:5698–5704. doi:10.1158/1078-0432.CCR-06-0181
 68. Husain H, Savage W, Grossman SA, Ye X, Burger PC, Ever-
ett A, Bettegowda C, Diaz LA, Blair C, Romans KE, Holdhoff 
M (2012) Pre- and post-operative plasma glial fibrillary acidic 
protein levels in patients with newly diagnosed gliomas. J Neu-
rooncol 109:123–127. doi:10.1007/s11060-012-0874-8
 69. Huttner HB, Janich P, Köhrmann M, Jászai J, Siebzehnrubl F, 
Blümcke I, Suttorp M, Gahr M, Kuhnt D, Nimsky C, Krex D, 
Schackert G, Löwenbrück K, Reichmann H, Jüttler E, Hacke W, 
Schellinger PD, Schwab S, Wilsch-Bräuninger M et al (2008) 
The stem cell marker prominin-1/CD133 on membrane parti-
cles in human cerebrospinal fluid offers novel approaches for 
studying central nervous system disease. Stem Cells 26:698–
705. doi:10.1634/stemcells.2007-0639
 70. Idbaih A, Omuro A, Ducray F, Hoang-Xuan K (2007) Molecu-
lar genetic markers as predictors of response to chemother-
apy in gliomas. Curr Opin Oncol 19:606–611. doi:10.1097/
CCO.0b013e3282f075f3
 71. Ilhan A, Gartner W, Neziri D, Czech T, Base W, Hörl WH, 
Wagner L (2009) Angiogenic factors in plasma of brain tumour 
patients. Anticancer Res 29:731–736
 72. Ilhan-Mutlu A, Wagner L, Preusser M (2013) Circulating bio-
markers of CNS tumors: an update. Biomark Med 7:267–285. 
doi:10.2217/bmm.13.12
 73. Ilhan-Mutlu A, Wagner L, Widhalm G, Wöhrer A, Bartsch S, 
Czech T, Heinzl H, Leutmezer F, Prayer D, Marosi C, Base W, 
Preusser M (2013) Exploratory investigation of eight circulating 
plasma markers in brain tumor patients. Neurosurg Rev 36:45–
55. doi:10.1007/s10143-012-0401-6 (discussion 55–56)
 74. Ilhan-Mutlu A, Wagner L, Wöhrer A, Furtner J, Widhalm G, 
Marosi C, Preusser M (2012) Plasma MicroRNA-21 concentra-
tion may be a useful biomarker in glioblastoma patients. Cancer 
Invest 30:615–621. doi:10.3109/07357907.2012.708071
 75. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, 
Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, 
Nedergaard M (2012) A paravascular pathway facilitates CSF 
flow through the brain parenchyma and the clearance of inter-
stitial solutes, including amyloid β. Sci Transl Med 4:147ra111. 
doi:10.1126/scitranslmed.3003748
 76. Iwadate Y, Hayama M, Adachi A, Matsutani T, Nagai Y, Hiwasa 
T, Saeki N (2008) High serum level of plasminogen activator 
inhibitor-1 predicts histological grade of intracerebral gliomas. 
Anticancer Res 28:415–418
 77. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi 
M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAnge-
lis LM, Holland EC, Hormigo A (2011) Serum YKL-40 is a 
marker of prognosis and disease status in high-grade gliomas. 
Neuro Oncol 13:1244–1251. doi:10.1093/neuonc/nor117
 78. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler 
JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response 
and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 
6:327–338. doi:10.1038/nrclinonc.2009.63
 79. Jelkmann W (2001) Pitfalls in the measurement of circulating 
vascular endothelial growth factor. Clin Chem 47:617–623
 80. Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V, 
Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diag-
nostic marker for glioblastoma multiforme. Brain 130:3336–
3341. doi:10.1093/brain/awm263
 81. Khleif SN, Doroshow JH, Hait WN (2010) AACR-FDA-NCI 
cancer biomarkers collaborative consensus report: advancing 
the use of biomarkers in cancer drug development. Clin Cancer 
Res 16:3299–3318. doi:10.1158/1078-0432.CCR-10-0880
 82. Khwaja FW, Nolen JDL, Mendrinos SE, Lewis MM, Olson JJ, Pohl 
J, Van Meir EG, Ritchie JC, Brat DJ (2006) Proteomic analysis of 
cerebrospinal fluid discriminates malignant and nonmalignant dis-
ease of the central nervous system and identifies specific protein 
markers. Proteomics 6:6277–6287. doi:10.1002/pmic.200600135
 83. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, 
Guha A, Groves MD, Kesari S, Pohl J, Van Meir EG (2007) 
Proteomic identification of biomarkers in the cerebrospinal 
fluid (CSF) of astrocytoma patients. J Proteome Res 6:559–570. 
doi:10.1021/pr060240z
 84. Kikuchi K, Gotoh H, Kowada M (1987) Immunosuppressive 
acidic protein in patients with brain tumours: a preliminary report. 
Acta Neurochir (Wien) 86:42–49. doi:10.1007/BF01419503
 85. Klement GL, Yip T-T, Cassiola F, Kikuchi L, Cervi D, Podust 
V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog 
N, Kieran MW, Folkman J (2009) Platelets actively sequester 
angiogenesis regulators. Blood 113:2835–2842. doi:10.1182/
blood-2008-06-159541
 86. Koppers-Lalic D, Hackenberg M, Bijnsdorp IV, van Eijndhoven 
MAJ, Sadek P, Sie D, Zini N, Middeldorp JM, Ylstra B, de 
Menezes RX, Würdinger T, Meijer GA, Pegtel DM (2014) Non-
templated nucleotide additions distinguish the small rna compo-
sition in cells from exosomes. Cell Rep. 8:1–10. doi:10.1016/j.
celrep.2014.08.027
862 Acta Neuropathol (2015) 129:849–865
1 3
 87. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive 
C (2014) Molecular analysis of circulating tumour cells-biology 
and biomarkers. Nat Rev Clin Oncol 11:129–144. doi:10.1038/
nrclinonc.2013.253
 88. Kros JM, Mustafa DM, Dekker LJM, Sillevis Smitt PAE, 
Luider TM, Zheng P-P (2014) Circulating glioma biomarkers. 
Neuro Oncol. doi:10.1093/neuonc/nou207
 89. Kumar DM, Thota B, Shinde SV, Prasanna KV, Hegde AS, Ari-
vazhagan A, Chandramouli BA, Santosh V, Somasundaram K 
(2010) Proteomic identification of haptoglobin α2 as a glioblastoma 
serum biomarker: implications in cancer cell migration and tumor 
growth. J Proteome Res 9:5557–5567. doi:10.1021/pr1001737
 90. Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, 
Ushio Y (1993) Quantitative study of monocyte chemoattract-
ant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from 
patients with malignant glioma. J Natl Cancer Inst 85:1836–1839
 91. Lange RP, Everett A, Dulloor P, Korley FK, Bettegowda C, Blair C, 
Grossman SA, Holdhoff M (2014) Evaluation of eight plasma pro-
teins as candidate blood-based biomarkers for malignant gliomas. 
Cancer Invest 32:423–429. doi:10.3109/07357907.2014.933237
 92. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T (2010) 
Serum DNA can define tumor-specific genetic and epigenetic 
markers in gliomas of various grades. Neuro Oncol 12:173–
180. doi:10.1093/neuonc/nop041
 93. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA 
in the serum of cancer patients and the effect of therapy. Cancer 
Res 37:646–650
 94. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Jiang T, 
Zhang W, Song SW (2009) Plasma IGFBP-2 levels predict clin-
ical outcomes of patients with high-grade gliomas. Neuro Oncol 
11:468–476. doi:10.1215/15228517-2008-114
 95. Lin Y, Wang J-F, Gao G-Z, Zhang G-Z, Wang F-L, Wang Y-J 
(2013) Plasma levels of tissue inhibitor of matrix metallopro-
teinase-1 correlate with diagnosis and prognosis of glioma 
patients. Chin Med J (Engl) 126:4295–4300
 96. Liu B-L, Cheng J-X, Zhang W, Zhang X, Wang R, Lin H, Huo 
J-L, Cheng H (2010) Quantitative detection of multiple gene 
promoter hypermethylation in tumor tissue, serum, and cer-
ebrospinal fluid predicts prognosis of malignant gliomas. Neuro 
Oncol 12:540–548. doi:10.1093/neuonc/nop064
 97. Locasale JW, Melman T, Song S, Yang X, Swanson KD, 
Cantley LC, Wong ET, Asara JM (2012) Metabolomics of 
human cerebrospinal fluid identifies signatures of malignant 
glioma. Mol Cell Proteomics 11(M111):014688. doi:10.1074/
mcp.M111.014688
 98. Lombardi G, Corona G, Farina P, Pambuku A, Bellu L, Della 
Puppa A, Fiduccia P, Bertorelle R, Paola Gardiman M, Toffoli 
GZV (2014) Diagnostic value of plasma and urinary 2-hydroxy-
glutarate to identify patients with IDH-mutated glioma. J Clin 
Oncol 32:5s (suppl; abstr 2037)
 99. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, 
Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO 
classification of tumours of the central nervous system. Acta 
Neuropathol 114:97–109. doi:10.1007/s00401-007-0243-4
 100. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von 
Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-
Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, 
Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M et al (2014) 
International Society of Neuropathology–Haarlem consensus 
guidelines for nervous system tumor classification and grading. 
Brain Pathol 24:429–435. doi:10.1111/bpa.12171
 101. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO 
classification of tumours of the central nervous system. IARC 
Press, Lyon
 102. Lyubimova NV, Toms MG, Popova EE, Bondarenko YV, 
Krat VB, Kushlinskii NE (2011) Neurospecific proteins in 
the serum of patients with brain tumors. Bull Exp Biol Med 
150:732–734
 103. Ma R, Zhang G, Wang H, Lv H, Fang F, Kang X (2012) Down-
regulation of miR-544 in tissue, but not in serum, is a novel 
biomarker of malignant transformation in glioma. Oncol Lett 
4:1321–1324. doi:10.3892/ol.2012.918
 104. Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta 
M, Chapman C, Lustig RA, Wileyto EP, Hahn SM, Dorsey JF 
(2014) Detection of brain tumor cells in the peripheral blood by 
a telomerase promoter-based assay. Cancer Res 74:2152–2159. 
doi:10.1158/0008-5472.CAN-13-0813
 105. Majchrzak-Celin´ska A, Paluszczak J, Kleszcz R, Magiera 
M, Barciszewska A-M, Nowak S, Baer-Dubowska W (2013) 
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF 
promoter methylation in circulating tumor-derived DNA of cen-
tral nervous system cancer patients. J Appl Genet 54:335–344. 
doi:10.1007/s13353-013-0149-x
 106. Manterola L, Guruceaga E, Gállego Pérez-Larraya J, González-
Huarriz M, Jauregui P, Tejada S, Diez-Valle R, Segura V, Sam-
prón N, Barrena C, Ruiz I, Agirre A, Ayuso A, Rodríguez J, 
González A, Xipell E, Matheu A, López de Munain A, Tuñón 
T et al (2014) A small noncoding RNA signature found in 
exosomes of GBM patient serum as a diagnostic tool. Neuro 
Oncol 16:520–527. doi:10.1093/neuonc/not218
 107. Martens T, Matschke J, Müller C, Riethdorf S, Balabanov S, 
Westphal M, Heese O (2013) Skeletal spread of an anaplastic 
astrocytoma (WHO grade III) and preservation of histopatho-
logical properties within metastases. Clin Neurol Neurosurg 
115:323–328. doi:10.1016/j.clineuro.2012.05.025
 108. Martin-Villalba A, Okuducu AF, von Deimling A (2008) The 
evolution of our understanding on glioma. Brain Pathol 18:455–
463. doi:10.1111/j.1750-3639.2008.00136.x
 109. Masui K, Cloughesy TF, Mischel PS (2012) Review: molecu-
lar pathology in adult high-grade gliomas: from molecular 
diagnostics to target therapies. Neuropathol Appl Neurobiol 
38:271–291. doi:10.1111/j.1365-2990.2011.01238.x
 110. Matsuura H, Nakazawa S (1985) Prognostic significance of 
serum alpha 1-acid glycoprotein in patients with glioblastoma 
multiforme: a preliminary communication. J Neurol Neurosurg 
Psychiatry 48:835–837
 111. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, 
Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant 
KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, 
Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin 
DB et al (2008) Circulating microRNAs as stable blood-based 
markers for cancer detection. Proc Natl Acad Sci 105:10513–
10518. doi:10.1073/pnas.0804549105
 112. Møller HG, Rasmussen AP, Andersen HH, Johnsen KB, Hen-
riksen M, Duroux M (2013) A systematic review of micro-
RNA in glioblastoma multiforme: micro-modulators in the 
mesenchymal mode of migration and invasion. Mol Neurobiol 
47:131–144. doi:10.1007/s12035-012-8349-7
 113. Muller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, 
Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec 
M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl 
JB, Westphal M, Pantel K, Riethdorf S (2014) Hematogenous 
dissemination of glioblastoma multiforme. Sci Transl Med 
6:247ra101. doi:10.1126/scitranslmed.3009095
 114. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, 
Piskorz AM, Parkinson C, Chin S-F, Kingsbury Z, Wong ASC, 
Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Bren-
ton JD, Caldas C, Rosenfeld N (2013) Non-invasive analysis of 
acquired resistance to cancer therapy by sequencing of plasma 
DNA. Nature 497:108–112. doi:10.1038/nature12065
 115. Nakamizo S, Sasayama T, Shinohara M, Irino Y, Nishiumi 
S, Nishihara M, Tanaka H, Tanaka K, Mizukawa K, Itoh T, 
863Acta Neuropathol (2015) 129:849–865 
1 3
Taniguchi M, Hosoda K, Yoshida M, Kohmura E (2013) GC/
MS-based metabolomic analysis of cerebrospinal fluid (CSF) 
from glioma patients. J Neurooncol 113:65–74. doi:10.1007/
s11060-013-1090-x
 116. Nilsson RJA, Balaj L, Hulleman E, van Rijn S, Pegtel DM, 
Walraven M, Widmark A, Gerritsen WR, Verheul HM, Vander-
top WP, Noske DP, Skog J, Würdinger T (2011) Blood platelets 
contain tumor-derived RNA biomarkers. Blood 118:3680–3683. 
doi:10.1182/blood-2011-03-344408
 117. Noerholm M, Balaj L, Limperg T, Salehi A, Zhu LD, Hoch-
berg FH, Breakefield XO, Carter BS, Skog J (2012) RNA 
expression patterns in serum microvesicles from patients with 
glioblastoma multiforme and controls. BMC Cancer 12:22. 
doi:10.1186/1471-2407-12-22
 118. Olar A, Aldape KD (2014) Using the molecular classification 
of glioblastoma to inform personalized treatment. J Pathol 
232:165–177. doi:10.1002/path.4282
 119. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling 
J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS 
statistical report: primary brain and central nervous system 
tumors diagnosed in the United States in 2007-2011. Neuro 
Oncol 16(Suppl 4):iv1–iv63. doi:10.1093/neuonc/nou223
 120. Pantel K, Alix-Panabières C, Riethdorf S (2009) Cancer micro-
metastases. Nat Rev Clin Oncol 6:339–351. doi:10.1038/
nrclinonc.2009.44
 121. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt 
P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon 
R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, 
Tekleab H, Diaz LA et al (2008) An integrated genomic analy-
sis of human glioblastoma multiforme. Science 321:1807–1812. 
doi:10.1126/science.1164382
 122. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, 
Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, 
Louis DN, Rozenblatt-Rosen O, Suva ML, Regev A, Bernstein 
BE (2014) Single-cell RNA-seq highlights intratumoral het-
erogeneity in primary glioblastoma. Science 344:1396–1401. 
doi:10.1126/science.1254257
 123. Patrick Y, Wen SK (2008) Malignant gliomas in adults. N Engl 
J Med 359:1850. doi:10.1056/NEJMc086380 (author reply 
1850)
 124. Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z 
(2004) Angiogenic factors in the cerebrospinal fluid of patients 
with astrocytic brain tumors. Neurosurgery 55:562–568. 
doi:10.1227/01.NEU.0000134383.27713.9A
 125. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, 
Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams 
PM, Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular 
subclasses of high-grade glioma predict prognosis, delineate a 
pattern of disease progression, and resemble stages in neuro-
genesis. Cancer Cell 9:157–173. doi:10.1016/j.ccr.2006.02.019
 126. Preusser M (2014) Neuro-oncology: a step towards clinical 
blood biomarkers of glioblastoma. Nat Rev Neurol 10:681–682. 
doi:10.1038/nrneurol.2014.208
 127. Quaranta M, Divella R, Daniele A, Di Tardo S, Venneri MT, 
Lolli I, Troccoli G (2007) Epidermal growth factor receptor 
serum levels and prognostic value in malignant gliomas. Tumori 
93:275–280
 128. Rafat N, Beck GC, Schulte J, Tuettenberg J, Vajkoczy P (2010) 
Circulating endothelial progenitor cells in malignant gliomas. J 
Neurosurg 112:43–49. doi:10.3171/2009.5.JNS081074
 129. Restrepo L, Stafford P, Magee DM, Johnston SA (2011) Appli-
cation of immunosignatures to the assessment of Alzheimer’s 
disease. Ann Neurol 70:286–295. doi:10.1002/ana.22405
 130. Reynés G, Vila V, Fleitas T, Reganon E, Font de Mora J, Jordá 
M, Martínez-Sales V (2013) Circulating endothelial cells and 
procoagulant microparticles in patients with glioblastoma: 
prognostic value. PLoS One 8:e69034. doi:10.1371/journal.
pone.0069034
 131. Reynés G, Vila V, Martín M, Parada A, Fleitas T, Reganon E, 
Martínez-Sales V (2011) Circulating markers of angiogenesis, 
inflammation, and coagulation in patients with glioblastoma. J 
Neurooncol 102:35–41. doi:10.1007/s11060-010-0290-x
 132. Rhodes CH, Honsinger C, Sorenson GD (1994) Detection of 
tumor-derived DNA in cerebrospinal fluid. J Neuropathol Exp 
Neurol 53:364–368
 133. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, 
Delattre J-Y (2012) Primary brain tumours in adults. Lancet 
379:1984–1996. doi:10.1016/S0140-6736(11)61346-9
 134. Risitano A, Beaulieu LM, Vitseva O, Freedman JE (2012) Plate-
lets and platelet-like particles mediate intercellular RNA trans-
fer. Blood 119:6288–6295. doi:10.1182/blood-2011-12-396440
 135. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, 
Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii 
K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang 
H, Chen Y, Kernytsky A et al (2013) An inhibitor of mutant 
IDH1 delays growth and promotes differentiation of glioma 
cells. Science 340:626–630. doi:10.1126/science.1236062
 136. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, 
Eisele G, Weller M, Keller A (2011) A specific miRNA signa-
ture in the peripheral blood of glioblastoma patients. J Neuro-
chem 118:449–457. doi:10.1111/j.1471-4159.2011.07307.x
 137. Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuil-
leumier N (2013) Auto-antibodies as emergent prognostic 
markers and possible mediators of ischemic cardiovascular 
diseases. Clin Rev Allergy Immunol 44:84–97. doi:10.1007/
s12016-010-8233-z
 138. Roy R, Yang J, Moses MA (2009) Matrix metalloprotein-
ases as novel biomarkers and potential therapeutic targets 
in human cancer. J Clin Oncol 27:5287–5297. doi:10.1200/
JCO.2009.23.5556
 139. Nishikawa R, Saran F, Mason W, Wick W, Cloughesy TF, Hen-
riksson R, Hilton M, Garcia J, Vogt T, Pallaud C, Chinot OL 
(2013) Biomarker (BM) evaluations in the phase III AVAglio 
study of bevacizumab (Bv) plus standard radiotherapy (RT) and 
temozolomide (T) for newly diagnosed glioblastoma (GBM). J 
Clin Oncol 31 (suppl; abstr 2023^)
 140. Salkeni MA, Zarzour A, Ansay TY, McPherson CM, Warnick 
RE, Rixe O, Bahassi EM (2013) Detection of EGFRvIII mutant 
DNA in the peripheral blood of brain tumor patients. J Neu-
rooncol 115:27–35. doi:10.1007/s11060-013-1209-0
 141. Salmaggi A, Eoli M, Frigerio S, Ciusani E, Silvani A, Boiardi 
A (1999) Circulating intercellular adhesion molecule-1 (ICAM-
1), vascular cell adhesion molecule-1 (VCAM-1) and plasma 
thrombomodulin levels in glioblastoma patients. Cancer Lett 
146:169–172
 142. Sampath P, Weaver CE, Sungarian A, Cortez S, Alderson L, 
Stopa EG (2004) Cerebrospinal fluid (vascular endothelial 
growth factor) and serologic (recoverin) tumor markers for 
malignant glioma. Cancer Control 11:174–180
 143. Saratsis AM, Yadavilli S, Magge S, Rood BR, Perez J, Hill DA, 
Hwang E, Kilburn L, Packer RJ, Nazarian J (2012) Insights into 
pediatric diffuse intrinsic pontine glioma through proteomic 
analysis of cerebrospinal fluid. Neuro Oncol 14:547–560. 
doi:10.1093/neuonc/nos067
 144. Sato Y, Honda Y, Asoh T, Oizumi K, Ohshima Y, Honda E 
(1998) Cerebrospinal fluid ferritin in glioblastoma: evidence for 
tumor synthesis. J Neurooncol 40:47–50
 145. Sawaya R, Cummins C, Smith B, Kornblith P (1985) Plasma 
fibronectin in patients with brain tumors. Neurosurgery. 
16:161–165
864 Acta Neuropathol (2015) 129:849–865
1 3
 146. Schmidt C (2011) Larger companies dominate cancer com-
panion diagnostic approvals. Nat Biotechnol 29:955–957. 
doi:10.1038/nbt1111-955
 147. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D 
(2006) Increased concentrations of transforming growth factor 
beta1 and beta2 in the plasma of patients with glioblastoma. J 
Neurooncol 79:61–65. doi:10.1007/s11060-005-9116-7
 148. Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth 
CG, Stuerenburg HJ, Selle H (2010) Peptide screening of cer-
ebrospinal fluid in patients with glioblastoma multiforme. Eur J 
Surg Oncol 36:201–207. doi:10.1016/j.ejso.2009.07.010
 149. Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free 
nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 
11:426–437. doi:10.1038/nrc3066
 150. Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clini-
cal relevance of circulating cell-free microRNAs in cancer. Nat 
Rev Clin Oncol 11:145–156. doi:10.1038/nrclinonc.2014.5
 151. Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, 
Hochberg FH, Breakefield XO, Weissleder R, Lee H (2012) 
Protein typing of circulating microvesicles allows real-time 
monitoring of glioblastoma therapy. Nat Med 18:1835–1840. 
doi:10.1038/nm.2994
 152. Shao N, Wang L, Xue L, Wang R, Lan Q (2014) Plasma miR-
454-3p as a potential prognostic indicator in human glioma. 
Neurol Sci. doi:10.1007/s10072-014-1938-7
 153. Shnaper S, Desbaillets I, Brown DA, Murat A, Migliavacca E, 
Schluep M, Ostermann S, Hamou M-F, Stupp R, Breit SN, de 
Tribolet N, Hegi ME (2009) Elevated levels of MIC-1/GDF15 
in the cerebrospinal fluid of patients are associated with glio-
blastoma and worse outcome. Int J Cancer 125:2624–2630. 
doi:10.1002/ijc.24639
 154. Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, 
Deleyrolle LP (2011) The origins of glioma: E Pluribus Unum? 
Glia 59:1135–1147. doi:10.1002/glia.21143
 155. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-
Esteves M, Curry WT, Carter BS, Krichevsky AM, Breakefield 
XO (2008) Glioblastoma microvesicles transport RNA and pro-
teins that promote tumour growth and provide diagnostic bio-
markers. Nat Cell Biol 10:1470–1476. doi:10.1038/ncb1800
 156. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins 
VP, Marioni JC, Curtis C, Watts C, Tavaré S (2013) Intratumor 
heterogeneity in human glioblastoma reflects cancer evolution-
ary dynamics. Proc Natl Acad Sci 110:4009–4014. doi:10.1073/
pnas.1219747110
 157. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, 
Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, 
Hegde AS, Chandramouli BA, Santosh V, Rao MRS, Kondaiah 
V, Somasundaram K (2010) Identification of potential serum 
biomarkers of glioblastoma: serum osteopontin levels corre-
late with poor prognosis. Cancer Epidemiol Biomarkers Prev 
19:1409–1422. doi:10.1158/1055-9965.EPI-09-1077
 158. Strojnik T, Smigoc T, Lah TT (2014) Prognostic value of eryth-
rocyte sedimentation rate and C-reactive protein in the blood of 
patients with glioma. Anticancer Res 34:339–347
 159. Stupp R, Tonn J-C, Brada M, Pentheroudakis G (2010) High-
grade malignant glioma: ESMO Clinical Practice Guidelines 
for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 
5):v190–v193. doi:10.1093/annonc/mdq187
 160. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, 
Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn 
U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier 
A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO 
(2005) Radiotherapy plus concomitant and adjuvant temozolo-
mide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/
NEJMoa043330
 161. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones 
DTW, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool 
M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu X-Y, 
Fontebasso AM, Ryzhova M, Albrecht S et al (2012) Hotspot 
mutations in H3F3A and IDH1 define distinct epigenetic and 
biological subgroups of glioblastoma. Cancer Cell 22:425–437. 
doi:10.1016/j.ccr.2012.08.024
 162. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, 
Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, 
Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor 
TT, Louis DN, Toner M, Maheswaran S et al (2014) Brain tumor 
cells in circulation are enriched for mesenchymal gene expres-
sion. Cancer Discov. doi:10.1158/2159-8290.CD-14-0471
 163. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-
Kragten AT, Smitt PA, van Es CA, van den Bent MJ (2008) 
Incidence of early pseudo-progression in a cohort of malignant 
glioma patients treated with chemoirradiation with temozolo-
mide. Cancer 113:405–410. doi:10.1002/cncr.23562
 164. Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, 
Wick W, Weller M (2010) Molecular diagnostics of glio-
mas: the clinical perspective. Acta Neuropathol 120:585–592. 
doi:10.1007/s00401-010-0750-6
 165. Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, 
Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-
Branger D, Ouafik L, Chinot O (2014) Association of matrix 
metalloproteinase 2 plasma level with response and survival in 
patients treated with bevacizumab for recurrent high-grade gli-
oma. Neuro Oncol 16:392–399. doi:10.1093/neuonc/not226
 166. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J 
(2013) Diagnostic and therapeutic avenues for glioblastoma: no 
longer a dead end? Nat Rev Clin Oncol 10:14–26. doi:10.1038/
nrclinonc.2012.204
 167. Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression 
microarray analysis reveals YKL-40 to be a potential serum 
marker for malignant character in human glioma. Cancer Res 
62:4364–4368
 168. Tektonidou MG, Ward MM (2011) Validation of new biomark-
ers in systemic autoimmune diseases. Nat Rev Rheumatol 
7:708–717. doi:10.1038/nrrheum.2011.157
 169. The Cancer Genome Atlas research Network (2008) Compre-
hensive genomic characterization defines human glioblastoma 
genes and core pathways. Nature 455:1061–1068. doi:10.1038/
nature07385
 170. Van Thuijl HF, Ylstra B, Würdinger T, van Nieuwenhuizen 
D, Heimans JJ, Wesseling P, Reijneveld JC (2013) Genetics 
and pharmacogenomics of diffuse gliomas. Pharmacol Ther 
137:78–88. doi:10.1016/j.pharmthera.2012.09.002
 171. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta 
MG, Lastiri J, Sacerdote de Lustig E, de Kier Bal, Joffé E, Puri-
celli L (2007) Alteration of serum and tumoral neural cell adhe-
sion molecule (NCAM) isoforms in patients with brain tumors. J 
Neurooncol 83:135–144. doi:10.1007/s11060-006-9312-0
 172. Tykocinski ES, Grant RA, Kapoor GS, Krejza J, Bohman L-E, 
Gocke TA, Chawla S, Halpern CH, Lopinto J, Melhem ER, 
O’Rourke DM (2012) Use of magnetic perfusion-weighted 
imaging to determine epidermal growth factor receptor vari-
ant III expression in glioblastoma. Neuro Oncol 14:613–623. 
doi:10.1093/neuonc/nos073
 173. Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, 
Cannon RO, Quyyumi AA (2000) Effects of a single intracoro-
nary injection of basic fibroblast growth factor in stable angina 
pectoris. Am J Cardiol 85:1414–1419
 174. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilk-
erson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe 
G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, 
865Acta Neuropathol (2015) 129:849–865 
1 3
Winckler W, Gupta S, Jakkula L et al (2010) Integrated genomic 
analysis identifies clinically relevant subtypes of glioblastoma 
characterized by abnormalities in PDGFRA, IDH1, EGFR, and 
NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020
 175. Vos MJ, Postma TJ, Martens F, Uitdehaag BMJ, Blankenstein 
MA, Vandertop WP, Slotman BJ, Heimans JJ (2004) Serum 
levels of S-100B protein and neuron-specific enolase in glioma 
patients: a pilot study. Anticancer Res 24:2511–2514
 176. Wakabayashi T, Natsume A, Hatano H, Fujii M, Shimato S, Ito 
M, Ohno M, Ito S, Ogura M, Yoshida J (2009) P16 promoter 
methylation in the serum as a basis for the molecular diagno-
sis of gliomas. Neurosurgery 64:455–461. doi:10.1227/01.
NEU.0000340683.19920.E3 (discussion 461–462)
 177. Wang LG, Setlow RB (1989) Inactivation of O6-alkylguanine-
DNA alkyltransferase in HeLa cells by cisplatin. Carcinogen-
esis 10:1681–1684
 178. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, Xie K (2012) 
Plasma specific miRNAs as predictive biomarkers for diag-
nosis and prognosis of glioma. J Exp Clin Cancer Res 31:97. 
doi:10.1186/1756-9966-31-97
 179. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, 
Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, 
Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifen-
berger G, von Deimling A, Loeffler M (2009) Molecular pre-
dictors of progression-free and overall survival in patients with 
newly diagnosed glioblastoma: a prospective translational study 
of the German Glioma Network. J Clin Oncol 27:5743–5750. 
doi:10.1200/JCO.2009.23.0805
 180. Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson 
M, Wick W, Reifenberger G (2012) Personalized care in neuro-
oncology coming of age: why we need MGMT and 1p/19q test-
ing for malignant glioma patients in clinical practice. Neuro 
Oncol 14(Suppl 4):iv100–iv108. doi:10.1093/neuonc/nos206
 181. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen 
AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, 
Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, 
Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM 
(2010) Updated response assessment criteria for high-grade gli-
omas: response assessment in neuro-oncology working group. J 
Clin Oncol 28:1963–1972. doi:10.1200/JCO.2009.26.3541
 182. Wesseling P, Kros JM, Jeuken JWM (2011) The pathologi-
cal diagnosis of diffuse gliomas: towards a smart synthesis 
of microscopic and molecular information in a multidiscipli-
nary context. Diagn Histopathol 17:486–494. doi:10.1016/j.
mpdhp.2011.08.005
 183. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, 
von Deimling A, Plass C, Hegi M, Platten M, Reifenberger 
G (2014) MGMT testing-the challenges for biomarker-based 
glioma treatment. Nat Rev Neurol 10:372–385. doi:10.1038/
nrneurol.2014.100
 184. Wiencke J, Accomando W, Zheng S (2012) Epigenetic bio-
markers of T-cells in human glioma. Epigenetics. 7:1391–1402
 185. Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE 
(2013) Proteomic studies of urinary biomarkers for pros-
tate, bladder and kidney cancers. Nat Rev Urol 10:206–218. 
doi:10.1038/nrurol.2013.24
 186. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, 
O’Fallon JR, Jaeckle KA, Prados MD (2010) Joint NCCTG and 
NABTC prognostic factors analysis for high-grade recurrent 
glioma. Neuro Oncol 12:164–172. doi:10.1093/neuonc/nop019
 187. Wurdinger T, Deumelandt K, van der Vliet HJ, Wesseling P, de 
Gruijl TD (2014) Mechanisms of intimate and long-distance 
cross-talk between glioma and myeloid cells: how to break a 
vicious cycle. Biochim Biophys Acta Rev Cancer 1846:560–
575. doi:10.1016/j.bbcan.2014.10.003
 188. Xu BJ, An QA, Srinivasa Gowda S, Yan W, Pierce LA, Abel 
TW, Rush SZ, Cooper MK, Ye F, Shyr Y, Weaver KD, Thomp-
son RC (2012) Identification of blood protein biomarkers that 
aid in the clinical assessment of patients with malignant glioma. 
Int J Oncol 40:1995–2003. doi:10.3892/ijo.2012.1355
 189. Yamaguchi Y, Shao Z, Sharif S, Du X-Y, Myles T, Merchant 
M, Harsh G, Glantz M, Recht L, Morser J, Leung LLK (2013) 
Thrombin-cleaved fragments of osteopontin are overexpressed 
in malignant glial tumors and provide a molecular niche with 
survival advantage. J Biol Chem 288:3097–3111. doi:10.1074/
jbc.M112.362954
 190. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, Wang J, Li 
L, Zhou X, Li N, Pan H, Zhang J, Zen K, Zhang C-Y, Zhang 
C (2013) Identification of seven serum microRNAs from a 
genome-wide serum microRNA expression profile as potential 
noninvasive biomarkers for malignant astrocytomas. Int J Can-
cer 132:116–127. doi:10.1002/ijc.27657
 191. Yoshida J, Wakabayashi T (1994) Tenascin in cerebrospinal 
fluid is a useful biomarker for the diagnosis of brain tumour. J 
Neurol Neurosurg Psychiatry 57:1212–1215
 192. Yoshida S, Morii K (2000) Serum concentrations of soluble 
interleukin-2 receptor in patients with malignant brain tumors. 
J Surg Oncol 75:131–135
 193. Zheng P-P, Hop WC, Luider TM, Sillevis Smitt PA, Kros JM 
(2007) Increased levels of circulating endothelial progenitor 
cells and circulating endothelial nitric oxide synthase in patients 
with gliomas. Ann Neurol 62:40–48. doi:10.1002/ana.21151
 194. Zheng P-P, Luider TM, Pieters R, Avezaat CJJ, van den Bent 
MJ, Sillevis Smitt PA, Kros JM (2003) Identification of tumor-
related proteins by proteomic analysis of cerebrospinal fluid 
from patients with primary brain tumors. J Neuropathol Exp 
Neurol 62:855–862
 195. Zucker S, Cao J (2005) Measurement of matrix metalloprotein-
ases in serum of patients with melanoma: snarled in technical 
pitfalls. Clin Cancer Res 11:5069–5070. doi:10.1158/1078-
0432.CCR-05-0774
